Related Experiment Video

Updated: May 26, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

PSIP1 Orchestrates Immune Escape in Osteosarcoma: Insights From Single-Cell Analysis and Implications for

Simin Liu1, Hong Yan1, Wei Ku1

  • 1Department of Spinal Surgery, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, Hubei, China.

International Journal of Genomics
|May 25, 2026
PubMed
Abstract

Insights

This study identifies PSIP1 as a key driver of immune escape in osteosarcoma (OS). High PSIP1 expression predicts poor immunotherapy response and survival, highlighting its potential as a therapeutic target.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Osteosarcoma (OS) features a complex tumor microenvironment (TME) that often hinders immunotherapy effectiveness.
  • Identifying molecular mechanisms of immune escape (IE) is critical for enhancing treatment outcomes in OS.

Purpose of the Study:

  • To investigate the molecular drivers of immune escape in the OS tumor microenvironment.
  • To identify potential biomarkers for predicting immunotherapy response in osteosarcoma.

Main Methods:

  • Integrated single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data.
  • Applied high-dimensional weighted gene coexpression network analysis (hdWGCNA) to identify IE-associated gene modules.
  • Utilized functional enrichment and Gene Set Enrichment Analysis (GSEA).

Main Results:

  • PSIP1 was identified as a significant prognostic hub gene within IE-related modules, predominantly expressed in malignant cells.
  • High PSIP1 expression correlated with reduced overall survival across multiple patient cohorts.
  • PSIP1 was linked to suppressed immune effector functions (B-cell signaling, lymphocyte chemotaxis, NK cell cytotoxicity) and predicted poor response to checkpoint blockade immunotherapy.

Conclusions:

  • PSIP1 is a novel orchestrator of immune evasion in osteosarcoma.
  • PSIP1 serves as a promising predictive biomarker for immunotherapy resistance in OS.
  • Targeting PSIP1 may offer a strategy to overcome therapeutic resistance in osteosarcoma.

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...